Skip to main content

Advertisement

Log in

Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, et al. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011;18:932–8.

    Article  PubMed  Google Scholar 

  2. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543–9.

    Article  PubMed  Google Scholar 

  3. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–44.

    Article  PubMed  CAS  Google Scholar 

  4. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 2011;11:81–92.

    Article  PubMed  CAS  Google Scholar 

  5. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6. No abstract available.

    Article  PubMed  Google Scholar 

  6. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn. 2010;10(5):541–5.

    Article  PubMed  CAS  Google Scholar 

  7. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics. 2010;11(8):1039–43.

    Article  PubMed  CAS  Google Scholar 

  8. Roukos DH. Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices. 2011;8(4):409–13.

    Article  PubMed  Google Scholar 

  9. Roukos DH. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics. 2011;12(5):695–8.

    Article  PubMed  Google Scholar 

  10. Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.

    Article  PubMed  CAS  Google Scholar 

  11. Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–5.

    Article  PubMed  Google Scholar 

  12. Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices. 2010;7(6):723–6.

    Article  PubMed  CAS  Google Scholar 

  13. Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Personal Med. 2010;7(4):347–50.

    Article  CAS  Google Scholar 

  14. Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther. 2010;10(2):123–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Charalambos Batsis MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batsis, C. Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment. Ann Surg Oncol 18 (Suppl 3), 286–287 (2011). https://doi.org/10.1245/s10434-011-1980-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-1980-0

Keywords

Navigation